Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer
- PMID: 16837776
- DOI: 10.1159/000094416
Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer
Abstract
Polo-like kinase 1 (PLK1) participates in bipolar spindle formation and entry into mitosis. Chromosomal instability (CIN) is caused by abnormalities in spindle formation and chromosome segregation. In this study, we investigated the relationship of PLK1 overexpression to CIN, and compared the PLK1 status with clinicopathological parameters in 101 human urothelial carcinomas of the urinary bladder. Expression of PLK1 and the number of centrosomes were assessed by immunohistochemistry. Numerical aberrations of chromosomes 7, 9 and 17 spots that allowed estimation of CIN were evaluated by fluorescence in situ hybridization, and DNA ploidy was assessed by laser scanning cytometry. Cancers with a large intercellular variation in centromere copy number were defined as CIN cancers. Tumors with PLK1 overexpression were associated more frequently with CIN (p < 0.0001), DNA aneuploidy (p = 0.0007) and centrosome amplification (p = 0.0013) than those without. Overexpression of PLK1 was significantly related to higher pathological grade (p = 0.0024), multiple tumors (p = 0.0241) and positive urine cytology (p = 0.0192). These data suggest that a high level expression of PLK1 confers tumor progression advantages to urothelial cancer cells, although other factors are also involved.
Copyright 2006 S. Karger AG, Basel.
Similar articles
-
Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer.Cancer Genet Cytogenet. 2007 Apr 1;174(1):42-7. doi: 10.1016/j.cancergencyto.2006.11.012. Cancer Genet Cytogenet. 2007. PMID: 17350465
-
PLK1 Induces Chromosomal Instability and Overrides Cell-Cycle Checkpoints to Drive Tumorigenesis.Cancer Res. 2021 Mar 1;81(5):1293-1307. doi: 10.1158/0008-5472.CAN-20-1377. Epub 2020 Dec 29. Cancer Res. 2021. PMID: 33376114 Free PMC article.
-
High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.Urol Oncol. 2013 Oct;31(7):1222-30. doi: 10.1016/j.urolonc.2011.11.028. Epub 2011 Dec 20. Urol Oncol. 2013. PMID: 22192978
-
The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?Genes (Basel). 2019 Mar 11;10(3):208. doi: 10.3390/genes10030208. Genes (Basel). 2019. PMID: 30862113 Free PMC article. Review.
-
Polo-like kinase 1 (PLK1) signaling in cancer and beyond.Biochem Pharmacol. 2021 Nov;193:114747. doi: 10.1016/j.bcp.2021.114747. Epub 2021 Aug 26. Biochem Pharmacol. 2021. PMID: 34454931 Review.
Cited by
-
Cdk1, Plks, Auroras, and Neks: the mitotic bodyguards.Adv Exp Med Biol. 2008;617:41-56. doi: 10.1007/978-0-387-69080-3_4. Adv Exp Med Biol. 2008. PMID: 18497029 Free PMC article. Review. No abstract available.
-
Muscle-invasive urothelial bladder cancer: an update on systemic therapy.Ther Adv Urol. 2015 Dec;7(6):312-30. doi: 10.1177/1756287215607418. Ther Adv Urol. 2015. PMID: 26622317 Free PMC article. Review.
-
Chromosomal instability and acquired drug resistance in multiple myeloma.Oncotarget. 2017 Sep 11;8(44):78234-78244. doi: 10.18632/oncotarget.20829. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100463 Free PMC article. Review.
-
Regulating a key mitotic regulator, polo-like kinase 1 (PLK1).Cytoskeleton (Hoboken). 2018 Nov;75(11):481-494. doi: 10.1002/cm.21504. Epub 2018 Dec 7. Cytoskeleton (Hoboken). 2018. PMID: 30414309 Free PMC article. Review.
-
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.Nat Rev Drug Discov. 2010 Aug;9(8):643-60. doi: 10.1038/nrd3184. Nat Rev Drug Discov. 2010. PMID: 20671765 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous